Carbidopa/levodopa pharmacy errors in Parkinson's disease

Movement Disorders

Volumn 25, Issue 16, 2010, Pages 2867-2871

  Khadem, Nasim R ^a   Nirenberg, Melissa J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Carbidopa levodopa; Healthcare utilization; Outpatient; Parkinson; Pharmacy error; Prescription

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ARTICLE; CONTROLLED RELEASE FORMULATION; DISTRESS SYNDROME; DRUG SUBSTITUTION; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; MEDICAL STAFF; MEDICATION ERROR; MORBIDITY; OUTPATIENT; PARKINSON DISEASE; PATIENT EDUCATION; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTIPARKINSON AGENTS; CARBIDOPA; HUMANS; LEVODOPA; MEDICATION ERRORS; PARKINSON DISEASE; PHARMACIES; PROSPECTIVE STUDIES;

EID: 78650188389     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23311     Document Type: Article

References (28)

1. Frey D, Rahman A. Medication management: an evidence-based model that decreases adverse events. Home Healthc Nurse 2003; 21: 404-412.
2. Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007; 30: 379-407.
3. Cina JL, Gandhi TK, Churchill W, et al. How many hospital pharmacy medication dispensing errors go undetected?. Comm J Qual Patient Saf 2006; 32: 73-80.
4. Balkrishnan R, Foss CE, Pawaskar M, Uhas AA, Feldman SR. Monitoring for medication errors in outpatient settings. J Dermatolog Treat 2009; 20: 229-232.
5. Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HH. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis 1986; 39: 533-542.
6. Gandhi TK, Weingart SN, Seger AC, et al. Outpatient prescribing errors and the impact of computerized prescribing. J Gen Intern Med 2005; 20: 837-841.
7. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41: 1411-1426.
8. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107-1116.
9. Bates DW, Cullen DJ, Laird N, et al. ADE Prevention Study Group. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274: 29-34.
10. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother 2002; 36: 1238-1248.
11. Australian Council for Safety and Quality in Healthcare. Second national report on patient safety improving medication safety. Australian Council for Safety and Quality in Healthcare: 2002.
12. McCoy LK. Look-alike, sound-alike drugs review: include look-alike packaging as an additional safety check. Jt Comm J Qual Patient Saf 2005; 31: 47-53.
13. Walliser G, Grossberg R, Reed MD. Look-alike medications: a formula for possible morbidity and mortality in the long-term care facility. J Am Med Dir Assoc 2007; 8: 541-542.
14. Lambert BL, Lin SJ, Chang KY, Gandhi SK. Similarity as a risk factor in drug-name confusion errors: the look-alike (orthographic) and sound-alike (phonetic) model. Med Care 1999; 37: 1214-1225.
15. Lambert BL. Predicting look-alike and sound-alike medication errors. Am J Health Syst Pharm 1997; 54: 1161-1171.
16. Nirenberg MJ, Fahn S. The Role of Levodopa and Catechol-O-Methyltransferase Inhibitors. In: Schapira A., Olanow C. W., editors. Principles of treatment in Parkinson's disease. Philadelphia: Butterworth Heinemann Elsevier; 2005. p 3-24.
17. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72 (21 Suppl 4 ): S1-136.
18. Ahlskog J. Initial symptomatic treatment of Parkinson's disease. In: Adler C. H., Ahlskog J. E., editors. Parkinson's disease and movement disorders: diagnosis and treatment guidelines for the practicing physician, First edition: Humana Press; 2000. 124-132.
19. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58-63.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
21. Shamliyan TA, Duval S, Du J, Kane RL. Just what the doctor ordered. Review of the evidence of the impact of computerized physician order entry system on medication errors. Health Serv Res 2008; 43 (Part 1): 32-53.
22. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic Review. J Am Med Inform Assoc 2008; 15: 585-600.
23. Rupp MT, Warholak TL. Evaluation of e-prescribing in chain community pharmacy: best-practice recommendations. J Am Pharm Assoc 2008; 48: 364-370.
24. Horsky J, Kuperman GJ, Patel VL. Comprehensive analysis of a medication dosing error related to CPOE. J Am Med Inform Assoc 2005; 12: 377-382.
25. Koppel R, Metlay JP, Cohen A, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005; 293: 1197-1203.
26. Kaushal R, Kern LM, Barron Y, Quaresimo J, Abramson EL. Electronic prescribing improves medication safety in community-based office practices. J Gen Intern Med 2010.
27. Nirenberg, MJ. PD ExpertBriefing: Parkinson's Disease and its Treatment: Secrets, Myths and Misconceptions, 2009; Available at
28. Nirenberg MJ. Parkinson's disease secrets, myths and misconceptions; Parkinson's disease news & review. Winter: Parkinson's Disease Foundation; 2009, Available at